Immunocore Holdings PLC
IMCRHealthcare|Biotechnology|UK
$31.95
-1.18 (-3.56%)
Tangible Book
$7.75
Clinical Trials (20)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05549297 Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | Advanced Melanoma | P3 | Recruiting | 540 | RCT, Open-label | Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice |
| NCT06246149 Adjuvant Tebentafusp in High Risk Ocular Melanoma | Uveal Melanoma | P3 | Recruiting | 290 | RCT, Open-label | Tebentafusp |
| NCT06112314 IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | Advanced Melanoma | P3 | Recruiting | 680 | RCT, Open-label | Brenetafusp, Nivolumab, Nivolumab + Relatlimab |
| NCT06414590 Neoadjuvant Tebentafusp for Uveal Melanoma | Locally Advanced Unresectable Uveal Melanoma | P2 | Recruiting | 19 | Open-label | Tebentafusp-Tebn |
| NCT06070012 Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | Uveal Melanoma | P2 | Recruiting | 44 | Open-label | Tebentafusp |
| NCT04262466 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Select Advanced Solid Tumors | P1P2 | Active | 410 | Open-label | Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors |
| NCT05315258 Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma | Melanoma (Skin), Melanoma, Uveal | P2 | Active | 850 | Open-label | Tebentafusp |
| NCT06627244 Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma | Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver | P2 | Recruiting | 30 | Open-label | Tebentafusp |
| NCT06840119 Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | Cancer, HLA-A*02:01-positive | P1P2 | Recruiting | 600 | Open-label | IMC-R117C, Chemotherapy drug, Chemotherapy drug, Kinase inhibitor, Antiangiogenic Agent, Monoclonal antibody |
| NCT07156136 Study of IMC-P115C in Advanced PRAME-Positive Cancers | PRAME Positive, Cancer | P1 | Recruiting | 140 | Open-label | IMC-P115C |
| NCT02535078 Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | Malignant Melanoma | P1P2 | Withdrawn | — | Open-label | Tebentafusp (IMCgp100) |
| NCT03973333 Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab | Select Advanced Solid Tumors | P1P2 | Withdrawn | — | Open-label | IMC-C103C, Atezolizumab, IMC-C103C |
| NCT02570308 A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | Uveal Melanoma | P1P2 | Completed | 146 | Open-label | IMCgp100 |
| NCT03515551 Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers | Select Advanced Solid Tumors | P1P2 | Terminated | 29 | Open-label | IMCnyeso |
| NCT02889861 IMCgp100-401 Rollover Study | Malignant Melanoma | P2 | Terminated | 3 | Open-label | IMCgp100 |
| NCT03070392 Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | Uveal Melanoma | P2 | Completed | 378 | RCT, Open-label | IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab |
| NCT07493122 Study of IMC-S118AI in Type 1 Diabetes | Type 1 Diabetes, Type 1 Diabetes (T1D) | P1 | Not Yet Recruiting | 154 | RCT, Single-blind | IMC-S118AI |
| NCT01211262 Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma | Malignant Melanoma | P1 | Completed | 84 | Open-label | IMCgp100 |
| NCT05867056 Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection | Hepatitis B, Chronic | P1 | Withdrawn | — | Open-label | IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses, HBV HCC Module MAD |
| NCT04960891 A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp | Uveal Melanoma | AVAILABLE | — | — | Tebentafusp |